The Propensity for Long-Acting Cabotegravir and Rilpivirine Every Two Months Among HIV-Infected People Eligible for Treatment.

Francesca AlbertonSilvia NozzaAngelo Roberto RaccagniLaura GalliVincenzo SpagnuoloSimona BossolascoMassimo CernuschiDiana CanettiHamid HassonAntonella CastagnaNicola Gianotti

Published in: Journal of medical virology (2022)

Borghetti and coll. 1 recently evaluated the proportion of individuals who could be eligible for switching to a long-acting (LA) regimen with cabotegravir and rilpivirine. This article is protected by copyright. All rights reserved.

Keyphrases

hiv infected
hiv infected patients
antiretroviral therapy
replacement therapy